Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3876602 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3876602 | EXPERIMENTAL | Single ascending doses of LY3876602 administered intravenously (IV). |
| Placebo | PLACEBO_COMPARATOR | Placebo administered IV. |
| LY3876602 Part B (MAD) | EXPERIMENTAL | Multiple ascending doses of LY3876602 will be administered intravenously (IV). |
| Placebo: Part B (MAD) | PLACEBO_COMPARATOR | Placebo administered IV |
| Name | Type | Description |
|---|---|---|
| LY3876602 | DRUG | Administered IV. |
| Placebo | DRUG | Administered IV. |
Inclusion Criteria: * Male and female participants who are overtly healthy as determined by medical evaluation * Have a body mass index with the range of 18 and less than or equal to (≤) 32 kilograms per square meter (kg/m²) * Male or female participants of nonchildbearing potential Exclusion Crit...
LY3876602 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, and its specific therapeutic indication has not been established. It is not yet approved by regulatory authorities.
LY3876602 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational small molecule in healthy participants.
LY3876602 is in Phase 1 clinical development. A Phase 1 study has been completed, which was designed to evaluate the safety, tolerability, and pharmacokinetics of the drug in healthy participants. The drug remains investigational and has not been approved for any medical use.
LY3876602 has been studied in one clinical trial, identified as NCT06007638. This was a Phase 1, single and multiple ascending dose study conducted in healthy participants in the Netherlands. The trial enrolled 74 participants and has been completed.
LY3876602 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial was a Phase 1 study in healthy participants, and the drug has not yet demonstrated efficacy or received regulatory approval for any indication.